11:51:27 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-06 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-06-06 Ordinarie utdelning AZT 0.00 NOK
2024-06-05 Årsstämma 2024
2024-05-08 Kvartalsrapport 2024-Q1
2024-02-01 Bokslutskommuniké 2023
2023-11-02 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-06-07 Ordinarie utdelning AZT 0.00 NOK
2023-06-06 Årsstämma 2023
2023-05-04 Kvartalsrapport 2023-Q1
2023-02-02 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-06-23 Årsstämma 2022
2022-05-27 Ordinarie utdelning AZT 0.00 NOK
2022-04-28 Kvartalsrapport 2022-Q1
2022-01-27 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning AZT 0.00 NOK
2021-05-20 Årsstämma 2021
2021-04-22 Kvartalsrapport 2021-Q1
2021-01-28 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-08-19 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning AZT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-23 Kvartalsrapport 2020-Q1
2020-01-30 Bokslutskommuniké 2019
2020-01-06 Extra Bolagsstämma 2020
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-16 Ordinarie utdelning AZT 0.00 NOK
2019-05-15 Årsstämma 2019
2019-04-30 Kvartalsrapport 2019-Q1
2019-01-30 Bokslutskommuniké 2018
2018-10-18 Kvartalsrapport 2018-Q3
2018-08-16 Kvartalsrapport 2018-Q2
2018-05-09 Ordinarie utdelning AZT 0.00 NOK
2018-05-07 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-01 Bokslutskommuniké 2017
2017-10-19 Kvartalsrapport 2017-Q3
2017-08-17 Kvartalsrapport 2017-Q2
2017-05-12 Ordinarie utdelning AZT 0.00 NOK
2017-05-11 Årsstämma 2017
2017-04-27 Kvartalsrapport 2017-Q1
2017-02-02 Bokslutskommuniké 2016
2016-10-26 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-12 Ordinarie utdelning AZT 0.00 NOK
2016-05-11 Årsstämma 2016
2016-04-19 Kvartalsrapport 2016-Q1
2016-02-11 Bokslutskommuniké 2015
2016-02-11 Kapitalmarknadsdag 2016
2015-11-03 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-05-13 Ordinarie utdelning AZT 0.00 NOK
2015-05-12 Årsstämma 2015
2015-05-05 Kvartalsrapport 2015-Q1
2015-02-17 Bokslutskommuniké 2014
2014-11-05 Kvartalsrapport 2014-Q3
2014-08-13 Kvartalsrapport 2014-Q2
2014-05-15 Ordinarie utdelning AZT 0.00 NOK
2014-05-14 Årsstämma 2014
2014-04-30 Kvartalsrapport 2014-Q1
2014-02-14 Bokslutskommuniké 2013
2013-11-01 Kvartalsrapport 2013-Q3
2013-08-09 Kvartalsrapport 2013-Q2
2013-06-13 Kapitalmarknadsdag 2013
2013-05-28 Ordinarie utdelning
2013-05-27 Årsstämma 2013
2013-05-07 Kvartalsrapport 2013-Q1
2013-02-01 Extra Bolagsstämma 2013
2013-01-07 Bokslutskommuniké 2012
2012-11-06 Kvartalsrapport 2012-Q3
2012-08-10 Kvartalsrapport 2012-Q2
2012-05-07 Ordinarie utdelning AZT 0.00 NOK
2012-05-07 Årsstämma 2012
2012-05-07 Kvartalsrapport 2012-Q1
2012-02-21 Bokslutskommuniké 2011
2011-11-08 Kvartalsrapport 2011-Q3
2011-08-10 Kvartalsrapport 2011-Q2
2011-05-13 Kvartalsrapport 2011-Q1
2011-05-13 Årsstämma 2011
2011-05-12 Ordinarie utdelning
2011-02-17 Bokslutskommuniké 2010
2010-11-12 Kvartalsrapport 2010-Q3
2010-08-10 Kvartalsrapport 2010-Q2
2010-05-11 Kvartalsrapport 2010-Q1
2010-05-04 Årsstämma 2010
2010-03-03 Bokslutskommuniké 2009

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
ArcticZymes Technologies är verksamma inom bioteknik. Bolaget specialiserar sig inom forskning och utveckling av läkemedel för behandling av autoimmuna sjukdomar. Störst inriktning återfinns inom utveckling av glukaner, framtagande av immunstimulerande medel, samt analys av enzymer. Visionen är att testa och utveckla medicinen för att sedan föra vidare dessa i användning för RNA och DNA processer. Bolaget gick tidigare under namnet Biotec Pharmacon och har sitt huvudkontor i Tromsö.
2019-04-30 07:00:18
Tromsø, Norway, 30 April 2019 - Biotec Pharmacon (OSE: Biotec) announces its Q1
2019 results to 31 March 2019.
Highlights for Q1 2019

  · Group sales were up 4% to NOK 14.8 million (Q1 2018: NOK 14.2 million).
  · Gross profit for the Group improved 23% to NOK 12.0 million (Q1 2018: NOK
9.7 million) due to improvements in all high margin areas.
  · ArcticZymes had first quarter sales of NOK 7.9 million growing by 25% (Q1
2018: NOK 6.3 million).
  · Woulgan® continues to generate recurring revenues with NOK 1.2 million for
the quarter, up 140% (Q1 2018: NOK 0.5 million), driven primarily by good sales
in the German market.
  · Improvement in EBITDA to NOK -3.9 million (Q1 2018: NOK -5.1 million) as a
result of stronger sales in high margin areas.
  · Cash-flow for the quarter was NOK -3.5 million (Q1 2018: -10.6 million).

CEO Christian Jørgensen comments:

"We have seen improvements across the business and, in particular, ArcticZymes
and Woulgan® sales have improved significantly compared to the same quarter last
year. Even though our business dynamics are not quarter-by-quarter, it is a
solid start to the year."

"We have also continued to reduce our deficit through the combination of
stronger sales and tight cost control this quarter."

"We continue to add customers in our various business segments, which is a
strong signal of the relevance of our products not only to our demanding direct
customers but also, more broadly, we are addressing unmet end-user needs."

-Ends-

First Quarter 2019 Results Presentation and Webcast

A presentation by Biotec Pharmacon's CEO, Christian Jørgensen, and CFO, Børge
Sørvoll, will take place today, 30 April 2019, at 08:30 am CET at Hotel
Continental, Stortingsgata 24/26, Oslo

The presentation can also be followed as a live webcast from Hegnar TV on
https://webtv.hegnar.no/presentation.php?webcastId=97815170. It will be possible
to post questions through the webcast console.

The results, report and presentation for the first quarter 2019  will be
available on www.newsweb.no (https://protect
-eu.mimecast.com/s/ax_EC4xJkS8gx1SMlEBY?domain=newsweb.no) and on the Company's
homepage, www.biotec.no (https://protect-eu.mimecast.com/s/JfV3C1wDYUZ3XYhph
-Hn?domain=biotec.no) from 07:00 am on 30 April 2019.

- Ends -

For more information, please contact:

Biotec Pharmacon
CEO Christian JørgensenCFO  Tel: +47 47 79 24 57
Børge Sørvoll               Tel: +47 95 29 01 87
                            ir@biotec.no

Instinctif Partners
Melanie Toyne-Sewell /      Tel: +44 207 457 2020
Christelle Kerouedan        Biotecpharmacon@instinctif.com
/Deborah Bell

About Biotec Pharmacon ASA

Biotec Pharmacon is a Norwegian life sciences company focused on specialized,
novel enzyme and immunomodulating beta-glucan technology.

The Biotec Pharmacon Group is creating value from innovation in life science
markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its
technologies capitalize on more than three decades of world-class research at
the Arctic University of Tromsø to offer niche and high tech products in several
biotech segments.

ArcticZymes develops, manufactures and commercialises novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans
addressing high unmet healthcare needs, such as chronic wound healing and as an
adjuvant in vaccines against certain types of cancer relapse.

Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec
Pharmacon is headquartered in Tromsø, Norway, in the SIVA Innovation Centre.

Biotec Pharmacon's unique IP and capabilities are protected via a large
portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website: www.biotec.no.